News
StockStory.org on MSN2d
Immuno-Oncology Stocks Q2 In Review: Incyte (NASDAQ:INCY) Vs Peers
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...
Clinical Trials Arena on MSN4d
CytomX to continue Phase I ADC trial despite patient death
CytomX's Phase I trial of ADC CX-2051 in colorectal cancer will continue based on a decision made by a safety committee ...
Michael Burry's Scion Asset Management ended the first quarter more bullish on companies across different sectors and ...
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today provided an update on the CX-2051 Phase 1 stud ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback